PN0

Prinomastat

Created:	2011-02-10
Last modified:	2021-03-13

Find Related PDB Entry
3 entries where PN0 is found as a standalone ligand

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	49
Chiral Atom Count	1
Bond Count	51
Aromatic Bond Count	12

2D diagram of PN0

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	Prinomastat
Synonyms	(3S)-N-hydroxy-2,2-dimethyl-4-{[4-(pyridin-4-yloxy)phenyl]sulfonyl}thiomorpholine-3-carboxamide
Systematic Name (OpenEye OEToolkits)	(3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonyl-thiomorpholine-3-carboxamide
Formula	C₁₈ H₂₁ N₃ O₅ S₂
Molecular Weight	423.506
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	12.01	O=S(=O)(N1C(C(=O)NO)C(SCC1)(C)C)c3ccc(Oc2ccncc2)cc3
SMILES	CACTVS	3.370	CC1(C)SCCN([CH]1C(=O)NO)[S](=O)(=O)c2ccc(Oc3ccncc3)cc2
SMILES	OpenEye OEToolkits	1.7.0	CC1(C(N(CCS1)S(=O)(=O)c2ccc(cc2)Oc3ccncc3)C(=O)NO)C
Canonical SMILES	CACTVS	3.370	CC1(C)SCCN([C@H]1C(=O)NO)[S](=O)(=O)c2ccc(Oc3ccncc3)cc2
Canonical SMILES	OpenEye OEToolkits	1.7.0	CC1([C@@H](N(CCS1)S(=O)(=O)c2ccc(cc2)Oc3ccncc3)C(=O)NO)C
InChI	InChI	1.03	InChI=1S/C18H21N3O5S2/c1-18(2)16(17(22)20-23)21(11-12-27-18)28(24,25)15-5-3-13(4-6-15)26-14-7-9-19-10-8-14/h3-10,16,23H,11-12H2,1-2H3,(H,20,22)/t16-/m0/s1
InChIKey	InChI	1.03	YKPYIPVDTNNYCN-INIZCTEOSA-N

Drug Info: DrugBank

DrugBank ID	DB05100
Name	Prinomastat
Groups	investigational
Description	Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. As a lipophilic agent, prinomastat crosses the blood-brain barrier.
Synonyms	Prinomastat Prinomastatum
Indication	Investigated for use/treatment in brain cancer, lung cancer, and prostate cancer.
Categories	Enzyme Inhibitors Matrix Metalloproteinase Inhibitors Protease Inhibitors
CAS number	192329-42-3

Related Resource References

Resource Name	Reference
Pharos	CHEMBL75094
PubChem	466151
ChEMBL	CHEMBL75094
ChEBI	CHEBI:138885

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.